Devonian Health Group Inc. (TSXV: GSD)

Market Cap	28.16M
Revenue (ttm)	17.82M
Net Income (ttm)	-1.22M
Shares Out	148.22M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,000
Open	0.185
Previous Close	0.185
Day's Range	0.180 - 0.190
52-Week Range	0.075 - 0.350
Beta	1.38
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 19, 2024

About Devonian Health Group

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Luc Gregoire
• Employees: 8
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: GSD

Financial Performance

In 2024, Devonian Health Group's revenue was 17.82 million, an increase of 659.60% compared to the previous year's 2.35 million. Losses were -1.22 million, -73.38% less than in 2023.